Preventive Effectiveness of Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors
Abstract
Objective This study assessed the effectiveness of the recombinant zoster vaccine (RZV) in preventing herpes zoster (HZ) in rheumatoid arthritis (RA) patients treated with Janus kinase (JAK) inhibitors. Methods This was a retrospective analysis. The patients were categorized into vaccinated (n=74) and unvaccinated (n=120) groups. HZ incidence was compared using the Kaplan-Meier method, and vaccine effectiveness was estimated using inverse probability of treatment weighting (IPTW) to adjust for baseline confounding factors. Patients 194 Japanese RA patients were analyzed treated with JAK inhibitors at our institution from January 2020 to September 2024. Results The observation spanned 124.4 person-years in the vaccinated group and 256.2 in the unvaccinated group. HZ occurred in six vaccinated cases (4.8 per 100 person-years) versus 20 unvaccinated cases (7.8 per 100 person-years) (p=0.32). The overall efficacy of the vaccine was 59.1%. HZ incidence varied by JAK inhibitor: baricitinib (5.5 vs 9.9), upadacitinib (12.4 vs 6.2), and filgotinib (0.0 vs 1.6) per 100 person-years. Vaccinated patients who developed HZ had significantly lower lymphocyte counts and higher SDAI and CDAI scores. Conclusion Although not statistically significant, RZV vaccination tended to reduce the incidence of HZ in Japanese RA patients receiving JAK inhibitors. The effectiveness varied according to the type of JAK inhibitor, with lower lymphocyte counts and higher disease activity, and it may predict insufficient protection.
Related
- Effectiveness and safety of Janus Kinase inhibitors in patients with rheumatoid arthritis, results from a multicenter observational “real-life” GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study
- Cardiovascular risk assessment using the DAS28-GGT score in rheumatoid arthritis patients initiating JAK inhibitors: Results from the MAJIK-SFR registry
- Effectiveness, safety and persistence of filgotinib in rheumatoid arthritis with a specific focus on difficult-to-treat patients: results from a multicentre observational study.
- Effectiveness and safety of bee venom pharmacopuncture for rheumatoid arthritis-related pain and disease activity: a systematic review and meta-analysis.
- CO074 | WHOLE-BLOOD COAGULATION AND PLATELET DYNAMICS IDENTIFY DIFFERENTIAL PROTHROMBOTIC STATES IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK OR TNFⱭ INHIBITORS
BibTeX
@article{tabata2026preventive,
title = {{Preventive Effectiveness of Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors}},
author = {Yusuke Tabata and Shun Tanimura and Akemi Kitano and Yuhei Shibata and Ikuma Nakagawa and Megumi Matsuhashi and Masato Shimizu and Kazuhide Tanimura and Takao Koike},
journal = {Internal Medicine},
year = {2026},
month = jul,
doi = {10.2169/internalmedicine.6154-25},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/14/65_6154-25/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Preventive Effectiveness of Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors
AU - Yusuke Tabata
AU - Shun Tanimura
AU - Akemi Kitano
AU - Yuhei Shibata
AU - Ikuma Nakagawa
AU - Megumi Matsuhashi
AU - Masato Shimizu
AU - Kazuhide Tanimura
AU - Takao Koike
PY - 2026
DA - 2026/07/15
JO - Internal Medicine
DO - 10.2169/internalmedicine.6154-25
UR - https://www.jstage.jst.go.jp/article/internalmedicine/65/14/65_6154-25/_article
AB - Objective This study assessed the effectiveness of the recombinant zoster vaccine (RZV) in preventing herpes zoster (HZ) in rheumatoid arthritis (RA) patients treated with Janus kinase (JAK) inhibitors. Methods This was a retrospective analysis. The patients were categorized into vaccinated (n=74) and unvaccinated (n=120) groups. HZ incidence was compared using the Kaplan-Meier method, and vaccine effectiveness was estimated using inverse probability of treatment weighting (IPTW) to adjust for baseline confounding factors. Patients 194 Japanese RA patients were analyzed treated with JAK inhibitors at our institution from January 2020 to September 2024. Results The observation spanned 124.4 person-years in the vaccinated group and 256.2 in the unvaccinated group. HZ occurred in six vaccinated cases (4.8 per 100 person-years) versus 20 unvaccinated cases (7.8 per 100 person-years) (p=0.32). The overall efficacy of the vaccine was 59.1%. HZ incidence varied by JAK inhibitor: baricitinib (5.5 vs 9.9), upadacitinib (12.4 vs 6.2), and filgotinib (0.0 vs 1.6) per 100 person-years. Vaccinated patients who developed HZ had significantly lower lymphocyte counts and higher SDAI and CDAI scores. Conclusion Although not statistically significant, RZV vaccination tended to reduce the incidence of HZ in Japanese RA patients receiving JAK inhibitors. The effectiveness varied according to the type of JAK inhibitor, with lower lymphocyte counts and higher disease activity, and it may predict insufficient protection.
SN - 1349-7235
SN - 0918-2918
ER -